Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.

At the heart of the event was Organon’s commitment to empowering women through access to safe and effective family planning ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential ...

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...